Equities analysts expect that Akebia Therapeutics Inc (NASDAQ:AKBA) will report earnings of ($0.43) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Akebia Therapeutics’ earnings, with estimates ranging from ($0.53) to ($0.26). Akebia Therapeutics reported earnings per share of ($0.91) during the same quarter last year, which indicates a positive year-over-year growth rate of 52.7%. The business is scheduled to announce its next earnings results on Tuesday, March 24th.
According to Zacks, analysts expect that Akebia Therapeutics will report full year earnings of ($2.01) per share for the current year, with EPS estimates ranging from ($2.09) to ($1.82). For the next fiscal year, analysts forecast that the company will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.46) to ($1.09). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Akebia Therapeutics.
Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.09). Akebia Therapeutics had a negative net margin of 75.39% and a negative return on equity of 32.74%. The firm had revenue of $91.98 million during the quarter, compared to analysts’ expectations of $93.94 million.
In related news, CEO John P. Butler bought 50,000 shares of the stock in a transaction on Wednesday, November 20th. The stock was bought at an average price of $3.44 per share, with a total value of $172,000.00. Following the completion of the purchase, the chief executive officer now directly owns 63,700 shares in the company, valued at approximately $219,128. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Steven Keith Burke purchased 27,000 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were bought at an average price of $3.58 per share, with a total value of $96,660.00. Following the completion of the transaction, the senior vice president now owns 37,000 shares of the company’s stock, valued at $132,460. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 82,800 shares of company stock worth $288,554. 2.66% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in AKBA. BlackRock Inc. boosted its position in shares of Akebia Therapeutics by 20.6% during the 2nd quarter. BlackRock Inc. now owns 10,227,690 shares of the biopharmaceutical company’s stock worth $49,501,000 after purchasing an additional 1,745,307 shares during the period. Nuveen Asset Management LLC acquired a new position in Akebia Therapeutics during the second quarter worth $7,885,000. Point72 Asset Management L.P. lifted its stake in Akebia Therapeutics by 1,523.4% during the second quarter. Point72 Asset Management L.P. now owns 1,623,400 shares of the biopharmaceutical company’s stock worth $7,857,000 after purchasing an additional 1,523,400 shares in the last quarter. Man Group plc lifted its stake in Akebia Therapeutics by 58.8% during the second quarter. Man Group plc now owns 934,650 shares of the biopharmaceutical company’s stock worth $4,524,000 after purchasing an additional 346,242 shares in the last quarter. Finally, Sofinnova Investments Inc. boosted its position in shares of Akebia Therapeutics by 64.2% during the second quarter. Sofinnova Investments Inc. now owns 848,356 shares of the biopharmaceutical company’s stock worth $4,106,000 after buying an additional 331,595 shares during the period. 70.35% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:AKBA opened at $6.06 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.34 and a quick ratio of 0.82. The firm has a market capitalization of $723.13 million, a price-to-earnings ratio of -2.48 and a beta of 1.76. The company’s 50-day moving average is $4.28 and its two-hundred day moving average is $4.35. Akebia Therapeutics has a 1-year low of $2.99 and a 1-year high of $10.45.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
Featured Story: What is channel trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.